Polycystic ovary syndrome (PCOS) is the most common endocrinopathy seen in women of reproductive age. Clinical concerns relating to PCOS range from ovulatory infertility and menstrual disorders to risk of diabetes and cardiovascular disease. Hormonal contraceptives have been the mainstay of the management of common PCOS symptoms, such as menstrual irregularity and clinical stigmata of androgen excess (i.e., hirsutism and acne). An appreciation of the relevance of metabolic pathways in the pathophysiology of PCOS is relatively recent, and has translated into an expansion of the therapeutic strategies available for the management of PCOS.
Polycystic ovary syndrome (PCOS) is the most common endocrinopathy in women of reproductive age, with an approximate prevalence of 6-10 %. [1] [2] [3] Characterized by clinical features of hyperandrogenism (such as hirsutism) and/or biochemical androgen excess and ovulatory dysfunction, PCOS is additionally associated with a spectrum of comorbidities that include infertility, increased risk of type 2 diabetes and of cardiovascular disease (CVD), psychological burden, and risk of endometrial pathologies including endometrial cancer. [2] [3] [4] The therapeutic approach to PCOS entails a focus on the overt presenting complaint(s) (e.g., oligomenorrhea, clinical hyperandrogenism, ovulatory infertility) as well as on the metabolic burden that predisposes this patient population to a spectrum of comorbidities in the long run, including type 2 diabetes and CVD.
In this article, the authors have attempted to provide an overview of the treatment options that offer therapeutic benefit in PCOS.
Treatment Options for Targeting Common Symptoms

Combined Oral Contraceptives
Having long been used as the first-line treatment in PCOS management, combined oral contraceptives (COCs) offer not just menstrual regulation and endometrial protection, but also a benefit against cutaneous stigmata of hyperandrogenism in women with PCOS. [5] [6] [7] Mechanisms whereby COCs mediate improvements in PCOS-related symptoms include:
• a suppression of pituitary luteinizing hormone (LH), thereby reducing the stimulant effect of LH on androgen production by the ovarian theca cells;
• an increase in hepatic sex hormone binding globulin (SHBG) directly resulting from the estrogen component in the COC; the net effect is a decline in the free androgen levels and hence an improvement in the clinical features of hyperandrogenism (e.g., acne and hirsutism); and
• the antiproliferative effects of the progestin component of the COC formulation, which offers protection against proliferative endometrial pathologies that oligomenorrheic and insulin-resistant women are particularly at risk of.
The attainment of a predictable withdrawal bleeding pattern with the use of COCs is influenced to some extent by the dose of estrogen and type of progestin in the COC formulation. COC-related improvements in acne may be evident within weeks of initiating therapy, whereas any benefit against excess hair growth is slow to appear. While all available COC formulations are likely to offer a degree of cutaneous benefit, the inclusion of certain synthetic progestin formulations with innate antiandrogenic properties, such as drosperinone and cyproterone acetate, may offer additional advantages in terms of acne control.
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Progesterone-only Approach
In oligomenorrheic women, particularly in those with excess body mass, the use of progestins alone (when administered orally or via intramuscular, subcutaneous, or intrauterine delivery routes) can be efficacious in mitigating the risk of endometrial pathologies (such as endometrial hyperplasia and cancer) that are recognized in the setting of chronic annovulation and long-term exposure to unopposed estrogen (endogenous or exogenous). The successful use of intrauterine progesterone-releasing systems in cases of endometrial hyperplasia and early stages of endometrial cancer has also been described. 8, 9 Annovulatory and oligomenorrheic women who are deemed at a disproportionately higher risk of estrogen-related risks (such as thromboembolism) may thus benefit from a progestin-only approach, 10 as a strategy for managing the commonly encountered dysfunctional uterine bleeding and as prophylaxis against the risk of endometrial cancer.
Treatment Options for Managing Infertility
Impaired functioning of the hypothalamic-pituitary-ovarian (HPO) axis is well recognized to underlie the ovulatory dysfunction of PCOS. While oligo-ovulation is an obvious mechanism, other potential contributors to infertility (such as tubal disease and coexisting male factor) must be additionally screened for in the setting of PCOS-related infertility.
Selective Estrogen Receptor Modulators
Selective estrogen receptor modulators (SERMs) represent the prototype of drugs that are of proven efficacy in achieving ovulation induction.
Clomiphene Citrate
Clomiphene citrate (CC) is conventionally considered as the first-line treatment for the management of the normogonadotropic anovulation seen in PCOS. 
Antiandrogens
Given the risk of malformations, such as feminization of a male fetus, linked with antiandrogens, there has to be an imperative need for reliable contraception if these agents are to be prescribed to women of reproductive age who may be at risk of an unplanned pregnancy.
Antiandrogen therapy must be discontinued at least three months in advance of attempting conception. 
Glucocorticoids
Glucocorticoids in low doses may offer cutaneous benefit for those with hyperandrogenemia not responsive to the more commonly used strategies.
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Cyproterone Acetate
Cyproterone acetate (CA) is a synthetic steroid that binds to the steroid receptors, exerting progestogenic, antiandrogenic, and weak glucocorticoid-like activity. In combination with ethinyl estradiol in COC formulations (not available in the US), 28, 34 this agent has demonstrated efficacy in treating hirsutism in women with PCOS. In COC formulations, CA is used at a 2 mg dose. Although generally well tolerated, it has side effects including weight gain, edema, decreased libido, and headaches.
Treatment Options for Managing Metabolic Abnormalities
Insulin-sensitizing Drugs
Hyperinsulinemia and insulin resistance are recognized as being of pathophysiological relevance for the endocrine and metabolic milieu of PCOS. 3, [35] [36] [37] [38] They are further recognized to contribute to the hyperandrogenism of PCOS. In turn, the local androgen excess within the ovaries contributes to the ovarian follicular arrest that underlies the polycystic appearance of ovaries, a hallmark of the syndrome. Beyond its causative role in PCOS symptomatology, insulin resistance is central to the processes that underlie the predisposition of women affected by PCOS to long-term comorbidities including type 2 diabetes, CVD, and endometrial pathologies. Given this last fact, insulin-sensitizing strategies (including both pharmacotherapy and lifestyle modifications)
are commonly used in the management of PCOS.
Metformin
A safe and well tolerated drug that is of proven efficacy in the management and prevention of type 2 diabetes, metformin is one of the insulin-sensitizing drugs most commonly used in the management of PCOS. [39] [40] [41] [42] Its mechanism of action centralizes around a metabolic pathway through decrease in hepatic gluconeogenesis via activation of the AMP-kinase pathway. 41, 42 Improved ovulation rates are observed in a variable proportion of women with PCOS treated with metformin. An early meta-analysis that included 13 randomized controlled trials (RCTs)
investigating the effect of metformin compared with either placebo or no treatment, or with an ovulation-inducing agent in women with PCOS, demonstrated that metformin alone was effective in achieving ovulation in 46 % of recipients compared with 24 % in the placebo arm. 43 In addition, when metformin was added to CC, 76 % of the recipients in the combination arm achieved ovulation compared with 42 % receiving CC alone (number needed to treat=3.0).
Metformin's efficacy as an ovulation-inducing agent was, however, subsequently refuted in a large RCT that compared the efficacy of metformin or CC alone versus a combination of the two in achieving ovulation, pregnancy, and live birth. 44 Metformin alone emerged as a poor strategy for managing ovulatory infertility compared with CC;
however, improved ovulatory and live birth rates were observed in the combination group, suggesting a role for metformin as an adjunct to CC in managing ovulatory disorders of PCOS.
Most recently, in a multicenter, double-blind RCT undertaken in 320 women with PCOS, improved pregnancy and live birth rates were observed after a three-month pre-treatment with metformin (versus placebo)
followed by an ovulation-inducing therapy; metformin and placebo were continued until 12 weeks' gestation. 45 Significantly improved pregnancy and live birth rates were observed with metformin pre-treatment In contrast to its role in the management of PCOS-related infertility, which has come under much scrutiny, a consensus exists regarding the metabolic benefits of metformin in populations at risk of type 2 diabetes.
Significant reductions in fasting insulin concentrations and low-density lipoprotein (LDL) cholesterol and improvements in systolic and diastolic blood pressure are described with metformin use in women with PCOS; 42, 47, 48 a reduction in serum androgens is additionally described, albeit inconsistently. 47, 49 However, despite the many metabolic benefits of metformin, the current consensus is that data supporting the treatment of all PCOS patients with metformin are sparse; rather, a comprehensive metabolic evaluation should be undertaken to detect conditions that would benefit from metformin treatment, namely impaired glucose tolerance, impaired fasting glucose, metabolic syndrome, and increased LDL cholesterol. 50 A recent study compared the efficacy of metformin with lifestyle modification in 40 women with PCOS. 51 After six months of intervention, an improvement of menstrual pattern (by 67 %) and a reduction in body mass index were evident in both groups, whereas a reduction in circulating testosterone levels was observed in the metformin group only. Beyond its potential for direct metabolic benefit, metformin therapy can also facilitate weight loss in some patients, thus maximizing the net metabolic benefit. 51 In patients with PCOS, metformin is typically prescribed at doses ranging from 500 mg/day to 850 mg three times a day. 52 Higher doses have been shown to be more efficacious in contributing to net weight loss, particularly in the obese and morbidly obese PCOS population. 53 While metformin is a relatively well tolerated therapy, side effects that are commonly seen include gastrointestinal disturbances, such as bloating, gaseousness, loose bowel movements, and a loss in appetite; these gastrointestinal side effects may be ameliorated with the use of extended-release preparations of metformin. 52 Caution is required when considering metformin therapy in patients with renal dysfunction, as lactic acidosis-a life-threatening consequence-has been described with metformin therapy in this setting; reassuringly, abnormal renal function is an unlikely occurrence in the relatively young PCOS population. 52 More recently, concerns have been raised regarding a blunted ovarian response to exogenous gonadotropin therapy in women with PCOS and evidence of borderline ovarian reserve who were being treated with metformin. 54 While the mechanisms were not entirely evident, the authors implied that women with PCOS and compromised ovarian reserve may benefit from discontinuation of metformin therapy prior to the start of controlled ovarian hyperstimulation.
Thiazolidinediones
Thiazolidinediones (TZDs) belong to a family of peroxisome proliferator-activated receptor gamma (PPAR-g) agonists and act primarily by increasing peripheral glucose uptake. The PPAR-g is identified as a transcription factor that regulates adipogenesis as well as being involved in systemic insulin action. 55 The efficacy of TZDs in ameliorating insulin resistance and hyperinsulinemia and in improving ovarian hyperandrogenism has been observed in women with PCOS. [56] [57] [58] [59] Similar to metformin, the effects of TZDs on ovarian function and ovarian follicular development in PCOS have been studied, but with results that are less promising that those obtained with metformin alone. 57,58 A higher ovulation frequency was observed following a six-month treatment using a combination of metformin and a TZD, compared with a TZD alone. 58 Troglitazone was one of the earliest TZDs introduced in the treatment of PCOS; the drug, however, was withdrawn due to an unacceptable adverse effect profile that included acute liver failure. 60 Safer TZDs have since been introduced. A recent study reports on the effect of pioglitazone, one of the currently approved TZDs, on obesity in women with PCOS; a significant decrease was observed in parameters of central obesity (waist circumference, hip circumference, and waist:height ratio)
despite an overall increase in the total body weight and body mass index. 61 The 63, 64 Recent studies have demonstrated lower GIP levels in obese women with PCOS. 65, 66 Given that insulin resistance is of pathophysiological relevance to the endocrine and metabolic dysfunction of PCOS, the therapeutic benefit of incretin therapy in this population is plausible. 
Dipeptidyl Peptidase-4 Inhibitors
GLP-1 Agonists
GLP-1 agonists differ from the oral DPP-4 inhibitors in that they need to be injected. 64, 69, 70 Commercially available GLP-1 agonists are exenatide and liraglutide, but many additional ones are under development.
Exenatide improves glycemic control while reducing body weight and maintaining low rates of hypoglycemia. 69, 70 Liraglutide injected once daily has been shown to improve glycemic control in individuals with type 2 diabetes (up to a 1.5 % decrease in glycated hemoglobin) when used as monotherapy or in combination, while simultaneously decreasing weight. 70 A single study has explored the therapeutic efficacy of exenatide in the PCOS population, with encouraging results. 71 In this 24-week trial undertaken in 60 overweight oligo-ovulatory women with PCOS aged 18-40 years, participants were randomized to one of three treatment groups for 24 weeks: metformin alone at 1,000 mg twice daily, exenatide alone at 10 μg twice daily, or a combination of the two drugs. The primary outcome was menstrual frequency. Secondary outcome measures included changes in ovulation rate, insulin action, anthropometric measures, androgen levels, and inflammatory markers.
The drug combination was determined to be superior to the two drugs on their own in improving menstrual cyclicity, ovulation rate, free androgen index, and insulin sensitivity measures as well as in reducing weight and abdominal fat. A significant reduction in weight was observed in both groups given the incretin alone or in combination compared with the group given metformin alone (p=0.003). The authors rightly concluded that larger trials of longer duration are warranted to assess the long-term efficacy and safety of combined metformin and exenatide therapy in overweight women with PCOS.
Acarbose
The therapeutic efficacy of acarbose is attributable to its action on reducing glucose absorption in the gut and thus decreasing post-prandial insulin levels. [72] [73] [74] [75] The potential role of acarbose in PCOS has been studied, but its effects on insulin sensitivity parameters, body mass, and vascular function were inconsistent and there was no significant improvement of PCOS-related dyslipidemia. 74, 75 Adverse effects, predominantly gastrointestinal, are common, and potentially fatal hepatotoxicity has been reported. Inconsistent efficacy, bothersome side effects, and the risk of liver damage limit the role of this agent in clinical practice.
Inositol Steroisomers
Inositol is a member of the vitamin B complex family; two of its steroisomers, D-chiro-inositol (DCI) and myo-inositol (MYO), have been studied to determine whether they can improve insulin sensitivity and hence whether they are relevant in PCOS management. [76] [77] [78] [79] [80] Although earlier data had identified DCI as potentially efficacious, subsequent data failed to confirm its efficacy in PCOS. MYO, however, has shown consistent promise. Improved indices of insulin sensitivity, decrease in serum testosterone, and improved spontaneous ovulation and menstrual cyclicity have been described with the use of MYO in women with PCOS.
Additionally, non-statistical improvements in the severity of hirsutism In a prospective RCT of 113 women with PCOS, simvastatin was found to be superior to metformin alone in decreasing serum testosterone levels. 84 In another double-blind RCT that assigned 20 women with PCOS and LDL>100 mg/dl to atorvastatin (40 mg/day) or placebo for six weeks, atorvastatin was associated with a statistically significant reduction in diastolic blood pressure, total cholesterol, LDL cholesterol, triglycerides, and serum levels of androstenedione and dehydroepiandrosterone sulfate compared with placebo. 85 Interestingly, increased insulin levels were observed in the atorvastatin group, indicating worsening insulin sensitivity despite an improvement in other metabolic parameters; the long-term implications of this finding are unclear. In a head-to-head comparison of two statins (simvastatin and atorvastatin), both agents induced comparable improvement of lipid profile and lowering of CRP level; atorvastatin induced a more significant improvement of insulin resistance, whereas simvastatin was better at lowering testosterone in women with PCOS. 87 Another RCT compared metabolic and endocrine effects of treatment with simvastatin, metformin, and a combination of the two drugs; 113 women with PCOS completed the three-month trial. 88 Simvastatin was deemed superior to metformin alone, and the combination therapy was found to offer no added benefits to those of simvastatin alone.
In a novel study design, the efficacy of short-term statin therapy (eight weeks) for reproductive biology was assessed in 20 women with PCOS undergoing IVF. Statin use was terminated following the triggering of ovulation with human chorionic gonadotropin prior to egg retrieval. 89 The results from this prospective randomized, placebo-controlled trial of 20 mg/day simvastatin showed significant reductions of testosterone, total cholesterol, CRP, and vascular cell adhesion protein-1 in the simvastatin-treated group compared with controls. Although oocyte maturation, fertility, and clinical pregnancy rates were higher in the statin-treated group compared with placebo, these differences were not of statistical significance, suggesting a need for further clinical trials to clarify the impact of statins on reproductive physiology. 89 In summary, the use of statins in women with PCOS has been shown to have both metabolic and endocrine benefits; the observed reduction in circulating androgens, however, has not been shown to translate into any improvement in menstrual cyclicity or features of hyperandrogenism. Until further data clarify their facilitatory effects on reproductive performance, and given their potential for teratogenicity, statins should be used with caution and only under approved research protocols in women of reproductive age who seek pregnancy. 90 
Miscellaneous Opioid Receptor Antagonist
The rationale behind the use of opioid receptor antagonists in PCOS is based on the existing evidence of sympathetic overactivity and elevated β-endorphin release, phenomena that directly influence the release and action of insulin. 91 Naltrexone is an orally administered competitive non-selective opioid receptor antagonist and has been studied in the PCOS population with encouraging, albeit inconsistent results. 
